The present invention provides a pharmaceutical combination for treatment of Fabry disease and use thereof. The present invention relates to a pharmaceutical combination for treating Fabry disease, and the pharmaceutical combination includes (i) a protein which has mutations in an amino acid sequence of α-N-acetylgalactosaminidase and has α-galactosidase activity and (ii) an active site specific chaperone.
